INSIGHTS ON DRUG DEVELOPMENT

• Analyzing Biological Drug Effects In 3D

  Explore how 3D tumor microtissues paired with fluorescence-based assays offer scalable, high-sensitivity drug testing to deliver stronger signals and reproducible results compared to monolayer cultures.

• 384-Well Microplate Time Resolved Fluorescence (TRF) Immunoassay

  Examine how innovative sandwich ELISAs in a 384-well format can be utilized with a sensitive reader for high-throughput screening to quantify Human IgG and IFN gamma.

• Cell Cycle Mapping In Tumors With Advanced Technologies

  Discover how spatial profiling and advanced imaging tools are transforming drug discovery, featuring Wayne Stallaert’s lab’s work on cell cycle mapping and biomarker insights in cancer research.

• LC-UV-Based Synthetic Peptide Impurity Tracking And Reporting

  Explore a UPLC-UV method using Empower 3 Software to assess synthetic peptide purity. Learn how integrated tools streamline impurity tracking, data reporting, and compliance in peptide analysis workflows.

• Fast And Scalable Fc Quantitation In Supernatants

  3/24/2025

  In biopharmaceutical development, the Fc PAIA Titer assay offers a fast, cost-effective, and automatable solution for high-throughput Fc quantification to enhance efficiency, support research, and accelerate production advancements.

• Assessing The Success Of CRISPR Gene Therapies Using ddPCR Technology

  3/4/2026

  Achieve high-fidelity results in gene therapy research. Discover how absolute quantification overcomes traditional limitations to provide the precision needed for validating CRISPR edits.

• Improving Swallowing And Palatability With Patient‑Friendly Forms

  1/15/2026

  Improve medication adherence and health outcomes by developing patient-friendly dosage forms that enhance swallowability and palatability for pediatric, geriatric, and dysphagic populations.

• A Study To Assess Organoid Size And Cell Count From 3D Image Analysis

  4/4/2025

  Recent advancements in 3D patient-derived organoids (PDOs) offer improved predictive power over traditional 2D assays. Explore a patented bioprocess for PDO expansion that could revolutionize drug discovery, especially in oncology.

• Patented Process For Intermediates Useful For Deucravacitinib

  3/13/2026

  Discover how this patented synthetic approach to Deucravacitinib intermediates can improve yield, simplify purification, and support scalable, regulatory-aligned manufacturing.